Literature DB >> 33417066

Clinical research on the combined use of systemic chemotherapy and CT-guided radiofrequency ablation in treatment of lung cancer.

Feng Xu1, Zhigang Cai2, Beizheng Xu3, Jian Song1, Haiyan Liu1, Xuanmei Li1, Aibing Deng1, Xiaotang Wu4, Jun Chen5.   

Abstract

The purpose of this study is to describe the clinical efficacy and safety of the combined use of systemic chemotherapy and CT-guided radiofrequency ablation (RFA) in treatment of lung cancer. A panel of 256 patients with lung cancer who were admitted to our hospital from June 2017 to October 2019 were recruited. According to the treatment plan, the patients were divided into test group (n = 128) and control group (n = 128). Patients in the test group were treated by systemic chemotherapy combined with CT-guided RFA, while patients in the control group were given systemic chemotherapy only. After treatment, a comparative analysis was conducted in terms of clinical efficacy, level of tumor markers, and adverse reactions. Meanwhile, patients in the two groups were followed up for analysis of progression-free survival (PFS) and overall survival (OS). After treatment, the tumor objective response rate and disease control rate of patients in the test group were significantly higher than those in the control group. Besides, in patients of the test group, tumor markers, such as serum carcino-embryonic antigen, neuro-specific enolase, cytokeratin-19, and carbohydrate antigen-199, presented a remarkably lower level relative to those in the control group (p < 0.05). However, there was no significant difference observed with regard to the incidence of complications (p > 0.05). Additionally, patients in the test group were more likely to have better PFS and OS. Notably, we monitored that in the test group, superior clinical efficacy was achieved in patients with non-small cell lung cancer and lung adenocarcinoma relative to that in patients with small cell lung cancer and lung squamous cell carcinoma, respectively. The combined use of systemic chemotherapy and CT-guided RFA can produce good clinical efficacy in treatment of lung cancer. It is relatively safe and deserves promotion and application in clinic.
© 2021. The Author(s), under exclusive licence to Springer-Verlag London Ltd. part of Springer Nature.

Entities:  

Keywords:  CT-guided radiofrequency ablation; Lung cancer; Systemic chemotherapy

Mesh:

Year:  2021        PMID: 33417066     DOI: 10.1007/s10103-020-03222-9

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  15 in total

1.  Massive hemorrhage during radiofrequency ablation of a pulmonary neoplasm.

Authors:  Cynthia Vaughn; George Mychaskiw; Patrick Sewell
Journal:  Anesth Analg       Date:  2002-05       Impact factor: 5.108

2.  Uniportal VATS-a new era in lung cancer surgery.

Authors:  Calvin S H Ng; Diego Gonzalez-Rivas; Thomas A D'Amico; Gaetano Rocco
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

3.  Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version).

Authors:  Xiu-Yi Zhi; Jin-Ming Yu; Yuan-Kai Shi
Journal:  Cancer       Date:  2015-09-01       Impact factor: 6.860

4.  miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM.

Authors:  Qiancheng Song; Yuanfei Xu; Cuilan Yang; Zhenguo Chen; Chunhong Jia; Juan Chen; Yue Zhang; Pinglin Lai; Xiaorong Fan; Xuan Zhou; Jun Lin; Ming Li; Wenli Ma; Shenqiu Luo; Xiaochun Bai
Journal:  Cancer Res       Date:  2014-04-07       Impact factor: 12.701

5.  Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α.

Authors:  Brandon Faubert; Emma E Vincent; Takla Griss; Bozena Samborska; Said Izreig; Robert U Svensson; Orval A Mamer; Daina Avizonis; David B Shackelford; Reuben J Shaw; Russell G Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

6.  Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism.

Authors:  Anne M Strohecker; Eileen White
Journal:  Autophagy       Date:  2013-12-17       Impact factor: 16.016

7.  Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

Authors:  Geoffrey R Oxnard; Cloud P Paweletz; Yanan Kuang; Stacy L Mach; Allison O'Connell; Melissa M Messineo; Jason J Luke; Mohit Butaney; Paul Kirschmeier; David M Jackman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2014-01-15       Impact factor: 12.531

8.  Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features.

Authors:  Sarah Barthelmeß; Helene Geddert; Carsten Boltze; Evgeny A Moskalev; Matthias Bieg; Horia Sirbu; Benedikt Brors; Stefan Wiemann; Arndt Hartmann; Abbas Agaimy; Florian Haller
Journal:  Am J Pathol       Date:  2014-02-08       Impact factor: 4.307

9.  Autophagy is required for glucose homeostasis and lung tumor maintenance.

Authors:  Gizem Karsli-Uzunbas; Jessie Yanxiang Guo; Sandy Price; Xin Teng; Saurabh V Laddha; Sinan Khor; Nada Y Kalaany; Tyler Jacks; Chang S Chan; Joshua D Rabinowitz; Eileen White
Journal:  Cancer Discov       Date:  2014-05-29       Impact factor: 39.397

10.  Computed tomography-guided core needle biopsy of lung lesions: Diagnostic yield and correlation between factors and complications.

Authors:  Ying Wang; Wentao Li; Xinhong He; Guodong Li; Lichao Xu
Journal:  Oncol Lett       Date:  2013-11-12       Impact factor: 2.967

View more
  1 in total

1.  Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: A propensity-matched analysis.

Authors:  Wei-Yu Yang; Yu He; Qikang Hu; Muyun Peng; Zhe Zhang; Shouzhi Xie; Fenglei Yu
Journal:  Front Oncol       Date:  2022-08-23       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.